We also observed a significant decrease in migration of MSC and/or HEK-293, DAOY, and BCC cells expressing tGLI2 and the FHL2-GLI2 fusion protein as compared to controls when treated with Vismodegib (Fig. 6c) or cyclopamine (Supplementary Fig. 9c). This evidence concerns the gene GLI2 and skin basal cell carcinoma.